And now I would like to turn the call over to our president and chief executive officer, Dr. Euan Thomson. Euan?Euan Thomson Thank you, Tom. And thanks to everyone for joining us today for Accuray’s fourth quarter of fiscal year 2012 conference call. To help illustrate the main points discussed this afternoon, we have posted slides to the investor relations page of the Accuray website. This afternoon, I’ll review the progress in our strategic plan and provide an update on our outlook for fiscal 2013 and beyond. I will then turn the call over to Derek Bertocci who will provide a detailed financial review. As we’ve done in previous quarters, we’ll provide both GAAP and non-GAAP numbers. When Derek talks later, he will refer to both measures, but for the sake of clarity, I will refer only to the non-GAAP numbers, since they give you a clear picture of Accuray’s ongoing core operations. Today our results show that we have achieved good progress in our strategic plan, although we know there is still work to do. Fiscal 2012 was a year of transition at Accuray, as we integrated our acquisition of TomoTherapy. It represented the first year of our multiyear strategy and execution story. The first phase of our strategy centered on integrating the two companies, with a strong focus on solving the liability issues surrounding the TomoTherapy system. I’m pleased to report that we have now engineered solutions to TomoTherapy systems reliability issues, with upgraded technology that we’re in the process of rolling out to the field. The second phase of our strategy is to drive system orders and revenue growth through a major technology release that we will unveil at the ASTRO trade show next month. This aspect of the plan we were not able to announce until today for commercial reasons, but I’ll talk more about it in a few minutes.
And the final phase will be to accelerate earnings growth, but I’ll concentrate today on the first two phases since they represent the year we just concluded and the period we’re now entering. Let me first provide a review of the fourth quarter and full fiscal year 2012. During the fourth quarter, total revenue was $101.1 million. 15 units were installed and 23 units shipped.Total revenue for the fiscal 2012 was essentially unchanged from prior year when factoring nonrecurring platinum revenue and the difference in TomoTherapy product revenue accounting. This met a goal of maintaining revenue in the year in which we integrated two sales forces. For the full year of fiscal 2012, we placed 99 system orders into backlog, and we shipped 92. The number of new orders increased for both product lines internationally, offset by a decline in U.S. orders for both products. There was a net worldwide increase in orders for TomoTherapy systems over the prior year, and a year on year decline in CyberKnife orders, although I’m glad to report that Q4 was a strong quarter of CyberKnife orders. We believe this is a sign that we’re reversing the decline in the CyberKnife product revenue that we observed during the first year of integration. In the fourth quarter, we added $74.2 million in new orders to backlog. The rolling four quarter book-to-bill ratio is 1.02. For the past three quarters, the book-to-bill ratio was 1.12, and for Q4 it was 1.15. This indicates growing momentum in new order performance, a leading indicator of future revenue growth. I’ll now briefly review the environment in the U.S. As we announced last quarter, we have realigned our U.S. sales force to address our recent U.S. weakness. Although the business environment in the U.S. remains somewhat weak, in certain territories we continue to do well. Read the rest of this transcript for free on seekingalpha.com